Pharmaceutical

Emergent scores US medical countermeasure contracts worth over $250m

Emergent will supply vaccines for anthrax and smallpox, VIV for treating smallpox vaccine complications, and a botulism antitoxin.

Jul 4, 2024 - 04:00
Emergent scores US medical countermeasure contracts worth over $250m
Emergent will supply vaccines for anthrax and smallpox, VIV for treating smallpox vaccine complications, and a botulism antitoxin.
Read the original article

Tags:

Previous Article

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Next Article

EMA approves Sanofi’s Dupixent for COPD treatment in adults

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Vertex non-opioid therapy reduced pain in mid-stage trials, study shows

STAT+: Vertex non-opioid therapy reduced pain in mid-st...

Aug 3, 2023

Opinion: Listen: What we take for granted after 30 years of Prozac

Opinion: Listen: What we take for granted after 30 year...

Nov 29, 2023

Signal: Roche to buy ulcerative colitis drug from Roivant for $7.1bn

Signal: Roche to buy ulcerative colitis drug from Roiva...

Oct 23, 2023